EUCTR2020-005197-10-DE进行中（未招募）1 期
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1) - NAVAL-1
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 486
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Adult patients age =18 years or as permitted by applicable local regulations at the time of informed consent. Patients must be able to swallow whole tablets.
- •a. For patients with PTLD: Age =12 years and weighing =40 kg
- •2.EBV+ relapsed/refractory lymphoma following 2 or more prior systemic therapies
- •3. Patients must have received at least one course of an anti-CD20 immunotherapy, and at least one course of anthracycline-based chemotherapy
- •4.Hodgkin lymphoma: Must have received at least one course of antracycline-based chemotherapy. Patients with classical Hodgkin lymphoma should have failed or be ineligible for an anti-PD-1 agent and CD30-directed therapy.
- •5.For patients with ENKTL: Relapsed/ refractory disease following 1 or more prior systemic therapies. Patients must have failed an a sparaginase-containing regimen.
- •6. For patients with PTCL (PTCL, NOS and AITL): relapsed or refractory
- •disease following 1 or more prior systemic therapies with a curative
- •7. For patients with PTLD: Patients with relapsed or refractory EBV+ PTLD who have received at least one prior therapy must have received at least one course of an antiCD20 immunotherapy such as rituximab. For solid-organ transplant (SOT) patients, prior therapy also includes chemotherapy, administered concurrently or sequentially, unless
- •chemotherapy is inappropriate.
- •8.No available therapies in the opinion of the investigator.
- •9.Not eligible for high-dose chemotherapy with allogeneic/autologous stem cell transplantation or CAR-T Therapy.
- •10.Measurable disease per Lugano 2007.
- •11.ECOG performance status 0, 1, 2.
- •12.Adequate bone marrow function.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 433
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 33
排除标准
- •1.Presence or history of central nervous system (CNS) involvement by lymphoma.
- •2.Systemic anticancer therapy or CAR within 21 days.
- •3.Antibody (anticancer) agents within 28 days.
- •4.Less than 60 days from prior autologous hematopoietic stem cell or solid organ transplant.
- •5.Less than 90 days from prior allogeneic transplant.
- •6.Daily corticosteroids (=20 mg of prednisone or equivalent) within week prior to Cycle 1 Day 1.
- •7.Inability to take oral medication, malabsorption syndrome or any other gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption of nanatinostat and valganciclovir.
- •8.Active infection requiring systemic therapy (Excluding viral upper respiratory tract infections
研究者
相似试验
进行中（未招募）
1 期
anatinostat and Valganciclovir in R/R EBV+ Lymphoma (NAVAL-1”)EUCTR2020-005197-10-ITViracta Therapeutics, Inc.150
招募中
1 期
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasMedDRA version: 27.0Level: PTClassification code: 10071441Term: Epstein-Barr virus associated lymphoma Class: 100000004864CTIS2024-512717-41-00Viracta Therapeutics Inc.502
进行中（未招募）
1 期
anatinostat and Valganciclovir in R/R EBV+ Lymphoma (NAVAL-1”)EUCTR2020-005197-10-FRViracta Therapeutics, Inc.150
进行中（未招募）
1 期
anatinostat and Valganciclovir in R/R EBV+ Lymphoma (NAVAL-1”)Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory LymphomasMedDRA version: 21.0Level: PTClassification code 10071441Term: Epstein-Barr virus associated lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005197-10-ESViracta Therapeutics, Inc.150
进行中（未招募）
1 期
A study of Iclusig (ponatinib), an oral kinase-inhibitor treatment administered, by standard dose or reduced doses, for patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) who no longer benefit from, or who have an abnormal gene (T315I positive) marker for resistance to other kinase-inhibitor treatments.Chronic Phase Chronic Myeloid LeukemiaMedDRA version: 21.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-001617-12-SETakeda Development Center Americas, Inc.276